

## BIOGRAPHICAL SKETCH

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.

Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Terry L. Moore, M.D.	POSITION TITLE  Director, Division of Adult and Pediatric Rheumatology		
eRA COMMONS USER NAME mooretl			
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
University of Michigan, Ann Arbor, MI University of Missouri, Columbia, MO Saint Louis University, School of Medicine, St. Louis, MO Saint Louis University Hospitals, St. Louis, MO Scripps Clinic and Research Foundation, La Jolla, CA	A.B.  M.D. (5/72)	1964-1965 1965-1968  1968-1972 1972-1974 1974-1976	Chemistry (cum laude)  Medicine Resident in Internal Med. Fellow in Rheumatology and Immunology

**A. Personal statement** – For the past 34 years, my laboratory has been committed to the study of immunological mechanisms in juvenile idiopathic arthritis (JIA) and systemic lupus erythematosus (SLE). We are pleased to participate in your studies on Novel Mechanisms of Apoptotic Cell-mediated Chronic Inflammation in SLE”. We will obtain clinical samples from SLE patients for identification of the IL-17-producing inflammatory monocytes. We will also perform antibody studies on these samples to correlate your results with disease status. We have one of the largest Adult and Pediatric Rheumatology Centers in the country caring for over 400 patients with SLE. Our clinic is one of the largest in the country, now open for approximately 40 years. We have a strong research team in our Division studying autoimmune disease including SLE with support from the NIH (1RO1 AI098114) presently and private foundations. I believe this study will answer one important question in the field of the role of apoptotic cells in chronic inflammation in patients with SLE. The results will help us understand the pathogenesis of SLE and may lead to identification of IL-17-producing inflammatory monocytes as a possible biomarker or therapeutic target in SLE.

### **B. Positions and Honors**

#### **Professional Experience**

1976-1980	Assistant Professor of Internal Medicine, Division of Rheumatology, Saint Louis University School of Medicine, St. Louis, MO
1980-1985	Associate Professor of Internal Medicine and Pediatrics, Division of Rheumatology, Saint Louis University School of Medicine
1981-	Director, Division of Pediatric Rheumatology, Cardinal Glennon Children’s Hospital, Department of Pediatrics, Saint Louis University School of Medicine
1983-	Director, Division of Rheumatology, Department of Internal Medicine, Saint Louis University School of Medicine
1985-	Professor of Internal Medicine and Pediatrics, Saint Louis University School of Medicine
2003-	Professor of Molecular Microbiology & Immunology, Saint Louis University School of Medicine

#### **National and International Grants and Grant Review Committees:**

1979-82	Clinical Investigator Award of the NIAMDD (NIH) (AM00364)
1983-88	Research Career Development Award of NIAMS (NIH) (AM-01036)
1985-91	<u>Member, National Institutes of Health, Study Section for Multipurpose Arthritis Center Grants</u>

1993-96	<u>Member, Ad Hoc Review Committee of National Institutes of Health for "Juvenile Rheumatic Disease Center Planning Grants"</u>
2001-2003	<u>Member, Ad Hoc Review Committee of National Institutes of Health for "Career Development Awards"</u>
2002-2003	Member, Ad Hoc Review Committee of American College of Rheumatology for "JRA Remission Criteria"
2004-2006	<u>Member, Ad Hoc Review Committee of National Institutes of Health for "Juvenile Arthritis and SLE Grants in Proteomics and Genomics and Immune Tolerance Mechanisms"</u>
2007-2008	Peer Research Grant Review Committee, Arthritis Foundation/American College of Rheumatology
2008-	<u>Member, Disease Monitoring, Safety Board of National Institutes of Health for Rilonacept in Treatment of Juvenile Idiopathic Arthritis</u>
2008-2012	<u>Peer Research Grant Review Committee, American College of Rheumatology/Research Education Fund (Chairman, Section C)</u>
2008-2009	<u>Member, Review Committee of National Institute of Health for "Autoimmune Center of Excellence Grants"</u>
2009-2010	<u>Member, Review Committee of National Institutes of Health for Grant Opportunity Challenge Grants</u>
2009-2011	<u>Member, Review Committee of National Institutes of Health for "NIH Loan Repayment Grants"</u>
2010-	<u>Member, Ad Hoc Review Committee of National Institutes of Health (NIAMS) Special Emphasis Panel</u>
2010-	<u>Member NIAID Clinical Trial Planning Grants (R34) and Implementation (U01) Cooperative Agreements</u>
2011-	<u>Member, Ad Hoc Review Committee of National Institutes of Health (NIH) for Arthritis and Musculoskeletal and Skin Diseases Special Grants</u>
<b>2012-2017</b>	<b><u>RO1 Award from NIAMS (NIH) (PI) (1RO1 AI098114)</u></b>

**Publications: Selected Publications: Total number: Full-length publications: 183 Abstracts: 209**

- Moore TL, Osborn TG, Neshor G: Immune complexes from sera of patients with juvenile rheumatoid arthritis reveal novel 40 and 60 kD bands. Clin Exp Rheumatol 13: 667-672, 1995
- Khalkhali-Ellis Z, Seftor EA, Nieva DRC, Seftor REB, Samaha HAM, Bultman L, DeLarco JE, Ince A, Moore TL, Hendrix MJC: Induction of invasive and degradative phenotype in normal synovial fibroblasts exposed to synovial fluid from juvenile rheumatoid arthritis patients: Role of mononuclear cell population. J Rheumatol 24: 2451-2460, 1997
- Khalkhali-Ellis Z, Roodman ST, Knutsen AP, Muller KR, Chauhan B, Moore TL, Hendrix MJC: Expression of Macrophage markers by a population of T-cells obtained from synovial fluid of a subgroup of patients with juvenile rheumatoid arthritis. J Rheumatol 25: 352-260, 1998
- Khalkhali-Ellis Z, Bulla G, Schlesinger LS, Kirschmann DA, Moore TL, Hendrix MJC: C1q containing immune complexes purified from the sera of juvenile rheumatoid arthritis patients mediate IL-8 production by human synoviocytes: Role of C1q receptors. J Immunol 163: 4612-4620, 1999
- Low JM, Chauhan AK, Kietz DA, Daud U, Pepmueller PH, Moore TL: Determination of anti-cyclic citrullinated peptide antibodies in the sera of patients with juvenile idiopathic arthritis. J Rheumatol 31:1829-1835, 2004
- Chauhan AK, Moore TL: Presence of plasma complement regulatory proteins clusterin (ApoJ) and vitronectin (S40) on circulating immune complexes. Clin Exp Immunol 145: 398-406, 2006
- Low JM, Chauhan AK, Moore TL: Abnormal kappa to lambda light chain ratio in circulating immune complexes from patients with juvenile idiopathic arthritis as a marker for B cell activity. Scand J Rheum 65: 76-83, 2007
- Syed RH, Gilliam BE, Moore TL: Prevalence and significance of isotypes of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis 67: 1049-1051, 2008
- Syed RH, Gilliam BE, Moore TL: Rheumatoid factors and anti-cyclic citrullinated peptide antibodies in pediatric rheumatology. Curr Rheum Reports 10: 156-163, 2008

Gilliam BE, Chauhan AK, Low JM, Moore TL: Measurement of biomarkers in juvenile idiopathic arthritis patients and their prediction of disease severity: a comparative study. Clin Exp Rheumatol 26: 492-497, 2008

Low JM, Chauhan AK, Gibson DS, Zhu M, Chen S, Rooney ME, Ombrello MJ, Moore TL: Proteomic analysis of circulating immune complexes in juvenile idiopathic arthritis reveals disease associated proteins. Proteomics Clin App 3: 829-840, 2009

Gilliam BE, Reed MR, Chauhan AK, Dehlendorf AB, Moore TL: Evidence of fibrinogen as a target of citrullination in IgM rheumatoid factor positive polyarticular juvenile idiopathic arthritis. Pediatr Rheumatol 9: 8: 1-16, 2011

Chauhan AK, Moore TL: T-cell activation by the terminal complex of complement and immune complexes. J Biol Chem 287: 38627-38637, 2011

Chauhan AK, Moore TL: Immune complexes and late complement proteins triggers activation of Syk tyrosine kinase in human CD4+ T cells. Clin Exp Immunol 167: 235-245, 2012

Gilliam BE, Ombrello AK, Burlingame R, Moore TL: Measurement of autoantibodies in pediatric and adolescent-onset systemic lupus erythematosus patients. Semin Arthritis Rheum 41: 840-848, 2012

## **RESEARCH SUPPORT- Terry L. Moore**

### **Active**

Title:	T-cell Activation by Immune Complexes and Complement in Autoimmunity
Agency:	National Institutes of Health
Period:	2012-2017 (PI)
Major Goal:	Analyze the Role of Signaling Events in Activation of T-cells by Immune Complexes in SLE
Title:	President's Research Award at Saint Louis University
Agency:	Saint Louis University
Period:	2011-2012 (PI)
Major Goal:	Glycosylation Studies in JIA
Title:	Research Award in JIA
Agency:	Dorr Charitable Trust Fund
Period:	2004-2013 (PI)
Major Goal:	Proteomic and Immune Complex Studies in JIA
Title:	Research Award in JIA and SLE
Agency:	Campbell-Avery Charitable Trust Fund
Period:	2004-2012 (PI)
Major Goal:	T-cell and Immune Complex Studies in SLE
Title:	ACR/REF Rheumatology Fellowship Training Award
Agency:	American College of Rheumatology
Period:	2008-2013 (PI)
Major Goal:	Partial Coverage of First Year Clinical Fellow's Salary
Title:	Lupus Research Award
Agency:	Lupus and Children's Arthritis Group of St. Louis
Period:	2009-2013 (PI)
Major Goal:	Studies in Immune Complexes in SLE and JIA